Connection
Breelyn Wilky to Receptor, IGF Type 1
This is a "connection" page, showing publications Breelyn Wilky has written about Receptor, IGF Type 1.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.125 |
|
|
|
-
Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015 Jan 06; 112(1):24-31.
Score: 0.125